1382991-60-7

Basic information

• Product Name: methyl 6-(3-fluorobenzyl)picolinate
• Synonyms: methyl 6-(3-fluorobenzyl)picolinate
• CAS NO: 1382991-60-7
• Molecular Weight: 245.253
• Mol File: 1382991-60-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 6-(3-fluorobenzyl)picolinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 6-(3-fluorobenzyl)picolinate(1382991-60-7)
• EPA Substance Registry System: methyl 6-(3-fluorobenzyl)picolinate(1382991-60-7)

Safety Data

• Hazardous Substances Data: 1382991-60-7(Hazardous Substances Data)

Upstream product

• 26218-75-7 methyl 6-Bromopicolinate 
• 934-60-1 6-methyl-2-pyridinecarboxylic acid 
• 768-35-4 3-fluorophenylboronic acid 
• 146462-25-1 methyl 6-(bromomethyl)picolinate 
• 13602-11-4 6-methylpicolinic acid methyl ester 

Downstream Products

• 1382991-61-8 6-(3-fluorobenzyl)picolinic acid 
• 1382992-77-9 N-(2-(5-chloro-1H-indol-3-yl)ethyl)-6-(3-fluorobenzyl)picolinamide 

Relevant articles and documents

Allosteric Inhibitors, Crystallography, and Comparative Analysis Reveal Network of Coordinated Movement across Human Herpesvirus Proteases

Targeting of cryptic binding sites represents an attractive but underexplored approach to modulating protein function with small molecules. Using the dimeric protease (Pr) from Kaposi's sarcoma-associated herpesvirus (KSHV) as a model system, we sought to dissect a putative allosteric network linking a cryptic site at the dimerization interface to enzyme function. Five cryogenic X-ray structures were solved of the monomeric protease with allosteric inhibitors bound to the dimer interface site. Distinct coordinated movements captured by the allosteric inhibitors were also revealed as alternative states in room-temperature X-ray data and comparative analyses of other dimeric herpesvirus proteases. A two-step mechanism was elucidated through detailed kinetic analyses and suggests an enzyme isomerization model of inhibition. Finally, a representative allosteric inhibitor from this class was shown to be efficacious in a cellular model of viral infectivity. These studies reveal a coordinated dynamic network of atomic communication linking cryptic binding site occupancy and allosteric inactivation of KHSV Pr that can be exploited to target other members of this clinically relevant family of enzymes.

NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.